Recent News Releases

Jul 7, 2020

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and...

Jun 30, 2020

Trading of Consolidated Shares on TSX Expected to Begin on July 3rd, 2020 VANCOUVER, BC, June 30, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN) (OTCQX:IMLFF), a...

Jun 24, 2020

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and...

Jun 19, 2020

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and...

See All News Releases

Letter to Shareholders

Annual Letter to Shareholders 2020

January 17, 2020

Download pdf

SEDAR® Filings
Loading data...
Financial Reports

Quarterly and Annual Financial Results

2020

Third quarter, 2020 (quarter ended March 31, 2020)
Second quarter, 2020 (quarter ended December 31, 2019)
First quarter, 2020 (quarter ended September 30, 2019)

2019

AGM Documents
Fourth quarter, 2019 (full year ended June 30, 2019)
Third quarter, 2019 (quarter ended March 31, 2019)
Second quarter, 2019 (quarter ended December 31, 2018)
First quarter, 2019 (quarter ended September 30, 2018)

2018

AGM Documents
Fourth quarter, 2018 (full year ended June 30, 2018)
Third quarter, 2018 (quarter ended March 31, 2018)
Second quarter, 2018 (quarter ended December 31, 2017)
First quarter, 2018 (quarter ended September 30, 2017)

2017

Fourth quarter, 2017 (full year ended June 30, 2017)
Third quarter, 2017 (quarter ended March 31, 2017)
Second quarter, 2017 (quarter ended December 31, 2016)
First quarter, 2017 (quarter ended September 30, 2016)

Stock Performance

-
Loading...
Display Events
 
 
 
 
Chart Style
Analyst Coverage
Firm Analyst E-mail Phone
Edison Investment Research Max Jacobs MJacobs@edisongroup.com +1 (646) 653-7027
Maxim Group, LLC Jason McCarthy, Ph.D. jmccarthy@maximgrp.com +1 (212) 895-3556
ROTH Capital Partners Scott R. Henry, CFA shenry@roth.com +1 (406) 425-0563